The brief

Analyst view

• RNS implanted near the focus, monitors EEG in real-time, delivers pulses automatically when seizure patterns detected.
• FDA approved focal drug-resistant epilepsy November 2013; NAUTILUS showed 77% generalized seizure reduction, awaiting IGE indication.
• IPO April 2021 on Nasdaq at $17/share, opening at $24.96. Current market cap ~$584M as of October 2026.

Technical approach

As reported

Sensing

Continuous EEG monitoring

RNS records brain activity from two implanted EEG leads, learns each patient's seizure pattern, and detects abnormal activity early.

Stimulation

Responsive electrical pulses

On detecting seizure activity, RNS delivers electrical pulses that disrupt the seizure pattern before it develops. Automatic, not patient-triggered.

Personalization

Patient-specific tuning

Doctors program based on each patient's seizure patterns, adjusting settings at clinic visits to optimize seizure control.